View Older Stories View More Recent Stories

Sep 14, 2022 07:00AM Altimmune (ALT) Reports Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide
Sep 14, 2022 07:00AM Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD
Aug 11, 2022 07:00AM Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
Aug 4, 2022 07:30AM Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
Jun 17, 2022 07:30AM Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
Jun 3, 2022 07:30AM Altimmune to Participate at Two Upcoming Investor Conferences
May 31, 2022 07:30AM Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
May 20, 2022 07:30AM Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
May 16, 2022 07:30AM Altimmune to Present at Upcoming Investor Conferences
May 12, 2022 07:00AM Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
May 5, 2022 07:30AM Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
Apr 1, 2022 07:02AM Altimmune (ALT) Initiates Phase 2 Trial of Pemvidutide in Obesity
Apr 1, 2022 07:00AM Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
Mar 15, 2022 07:01AM Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Mar 8, 2022 07:00AM Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
Jan 31, 2022 07:02AM Altimmune (ALT) Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Jan 31, 2022 07:00AM Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Jan 3, 2022 07:00AM Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
Dec 13, 2021 06:01AM Altimmune (ALT) Appoints Richard Eisenstadt as CFO
Dec 13, 2021 06:00AM Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
Dec 13, 2021 06:00AM Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 22, 2021 04:01PM Altimmune to Present at Upcoming Investor and Scientific Conferences
Nov 10, 2021 04:01PM Altimmune to Present at Upcoming Investor Conferences
Nov 9, 2021 04:01PM Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
Nov 3, 2021 04:01PM Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
Oct 6, 2021 04:01PM Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
Oct 4, 2021 07:00AM Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease
Sep 29, 2021 06:15PM Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
Sep 28, 2021 07:04AM Altimmune (ALT) Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
Sep 28, 2021 07:01AM Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
Sep 27, 2021 04:04PM Altimmune (ALT) to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28
Sep 27, 2021 04:01PM Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Sep 7, 2021 04:01PM Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
Aug 10, 2021 04:01PM Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
Aug 4, 2021 04:01PM Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021
Jun 29, 2021 04:02PM Altimmune (ALT) is discontinuing further development of AdCOVID
Jun 29, 2021 04:01PM Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
Jun 16, 2021 07:03AM Altimmune (ALT) Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
Jun 16, 2021 07:00AM Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
May 26, 2021 07:01AM Altimmune (ALT) Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID
May 26, 2021 07:00AM Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™
May 17, 2021 07:00AM Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update
May 11, 2021 07:00AM Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
May 10, 2021 07:00AM Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose
Apr 29, 2021 07:00AM Altimmune to Present at Upcoming Scientific Conferences
Apr 1, 2021 07:06AM Altimmune (ALT) Reports Data from its Phase 1b Clinical Trial of NasoShield
Apr 1, 2021 07:00AM Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
Mar 22, 2021 07:00AM Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate
Mar 15, 2021 07:05AM Altimmune (ALT) Announces AdCOVID Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
Mar 15, 2021 07:00AM AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
View More Recent Stories View Older Stories